Kazia Therapeutics Limited (KZIA) Key Metrics
KZIA key metrics, FY2016–FY2025
Fiscal year ended June 30, 2025 · Australian dollarsKZIA returns How much profit the business earns on the capital it uses.
KZIA financial health Debt, liquidity and how easily interest is covered.
KZIA efficiency & capital use Working capital cycle and where the cash goes.
KZIA returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
KZIA debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
KZIA key metrics in Australian dollars
FY2016–FY2025| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Returns & profitability | ||||||||||
| Return on equity (ROE) | — | — | −135.0% | −89.1% | −32.4% | −88.0% | −61.4% | −27.1% | −36.0% | −30.7% |
| Return on invested capital (ROIC) | — | — | −178.4% | −174.3% | −64.5% | −136.6% | −59.9% | −81.3% | −150.7% | — |
| Return on assets (ROA) | −149.8% | −107.8% | −64.0% | −53.2% | −20.8% | −56.4% | −41.6% | −18.8% | −29.9% | −29.5% |
| Return on tangible assets | −416.2% | −433.0% | −189.2% | −149.3% | −23.3% | −117.0% | −133.7% | −44.4% | −53.4% | −34.8% |
| Free cash flow margin | — | −415.1% | — | — | −60.0% | −891.6% | — | — | −130.2% | −307.2% |
| Financial health | ||||||||||
| Total debt | A$396,000 | A$634,000 | A$1.8M | A$1.8M | — | — | A$0 | A$84,000 | A$10,000 | A$10,000 |
| Cash & short-term investments | A$4.3M | A$1.7M | A$5.2M | A$7.4M | A$27.6M | A$8.8M | A$5.5M | A$6.0M | A$14.5M | A$33.5M |
| Net debt | −A$3.9M | −A$1.0M | −A$3.4M | −A$5.5M | −A$27.6M | −A$8.8M | −A$5.5M | −A$5.9M | −A$14.4M | −A$33.4M |
| Debt / equity | — | — | 0.15 | 0.10 | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt / assets | 0.07 | 0.03 | 0.06 | 0.05 | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
| Current ratio | 0.35 | 0.24 | 1.42 | 1.40 | 3.53 | 2.10 | 3.42 | 2.38 | 3.62 | 23.81 |
| Quick ratio | 0.35 | 0.24 | 1.93 | 1.40 | 3.54 | 2.10 | 4.12 | 2.38 | 3.62 | 23.50 |
| Interest coverage | — | — | — | — | -1.3 | -50.8 | -3.8 | — | -14.2 | — |
| Working capital | −A$9.1M | −A$19.7M | A$3.2M | A$2.7M | A$21.1M | A$5.6M | A$5.3M | A$5.4M | A$14.1M | A$32.7M |
| Invested capital | −A$12.2M | −A$11.0M | A$8.6M | A$12.8M | A$10.3M | A$5.4M | A$8.7M | A$13.4M | A$10.9M | A$488,000 |
| Tangible asset value | −A$9.4M | −A$25.4M | −A$5.2M | −A$864,000 | A$15.8M | A$1.7M | A$675,453 | A$4.7M | A$9.4M | A$33.1M |
| Net current asset value | −A$9.4M | −A$25.5M | −A$5.3M | −A$8.2M | A$9.2M | A$1.7M | A$534,440 | A$327,000 | A$8.9M | A$32.5M |
| Capital allocation | ||||||||||
| Dividends paid | — | — | — | — | — | — | A$0 | A$0 | A$0 | A$0 |
| Share buybacks (net) | — | — | — | — | — | — | A$0 | A$0 | A$0 | A$0 |
| Capex / revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 12.9% |
| Capex / depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.82 |
| Stock-based compensation / revenue | 1,554.8% | 23.1% | 208,828.8% | 16,750.0% | 4.2% | 26.5% | 15,718.8% | 1,258.8% | 5.9% | 9.1% |
| R&D / revenue | 17,442.9% | 753.0% | 2,804,336.9% | 201,690.0% | 95.8% | 960.9% | 413,801.9% | 74,565.2% | 126.7% | 243.0% |
| SG&A / revenue | 20,761.9% | 587.7% | 1,546,488.6% | 52,400.0% | 46.2% | 373.4% | 241,916.9% | 42,706.7% | 97.0% | 141.5% |
| Efficiency | ||||||||||
| Days sales outstanding | 969.0 | 18.8 | 51,297.3 | 2,317.8 | 0.9 | 287.8 | 181,767.2 | 86.3 | 2.0 | 4.2 |
| Receivables turnover | 0.38 | 19.39 | 0.01 | 0.16 | 397.26 | 1.27 | 0.00 | 4.23 | 182.96 | 87.55 |
| Payables turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory turnover | — | — | — | — | — | — | — | — | 0.00 | 0.00 |
| Asset turnover | 0.00 | 0.09 | 0.00 | 0.00 | 0.37 | 0.04 | 0.00 | 0.00 | 0.25 | 0.10 |
| Average receivables | A$111,500 | A$119,000 | A$78,000 | A$63,500 | A$38,220 | A$779,012 | A$779,358 | A$3,098 | A$48,034 | A$46,500 |
| Average payables | A$5.1M | A$2.7M | A$1.2M | A$1.7M | A$1.8M | A$1.4M | A$1.2M | A$1.3M | A$880,445 | A$638,750 |
| Average inventory | — | — | −A$3.8M | — | −A$41,999 | −A$776,000 | −A$776,000 | A$0 | A$217,000 | A$216,554 |
| Intangibles / total assets | 17.9% | 71.3% | 61.5% | 53.3% | 37.9% | 53.8% | 63.7% | 51.7% | 44.3% | 2.3% |
Computed from KZIA's annual financial statements (latest annual report filed November 7, 2025) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in Australian dollars; data from EODHD. Averages use the opening and closing balance of each year.
KZIA valuation and financial ratios
It ended the year with A$0.4 million of debt and A$4.3 million in cash and short-term investments, a net cash position of A$3.9 million.
See the KZIA income statement, the KZIA chart for price history, or the KZIA stock overview for the latest quote and news.
KZIA key metrics FAQ
How much debt does Kazia Therapeutics have?
Kazia Therapeutics had total debt of A$0.4 million at the end of fiscal 2025 and more cash than debt.
What is Kazia Therapeutics's current ratio?
Kazia Therapeutics's current ratio was 0.35 at the end of fiscal 2025: current assets were 0.35 times current liabilities.